Notably, a positive impact of the co-stimulatory ADA/CD26 axis has been recently reported on the functionality of CD8+PD-1+CD28+ T cells [43] in the immunosuppressive, CD39-enriched microenvironment of NSCLC [141], correlating with improved responses to ICB [43]. The gene discussed is CD28; the disease is non-small cell lung carcinoma.